Pregabalin
Product Images NDC 60760-486

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-486). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Prega (Pregabalin 60760 486 90)

Packaging label for Pregabalin Capsules 200mg, quantity of 90 capsules, labeled by St. Mary's Medical Park Pharmacy. The label includes the NDC 60760-486-90, barcode, and storage instructions to keep at controlled room temperature 15°-30°C (59°-86°F). Manufacturer is ScieGen Pharmaceuticals, Inc., Hauppauge, NY. The label includes placeholders for lot and expiration dates.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin at doses of 200 mg, 100 mg, and 25 mg three times a day with placebo, showing different levels of patient improvement across these groups.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day and placebo. The graph shows higher patient improvement percentages across pain improvement levels for Pregabalin relative to placebo.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line chart depicting percent of patients improved against percent improvement in pain from baseline. It compares Pregabalin at doses of 300 mg, 150 mg, and 75 mg taken twice daily, with a placebo group. The chart shows trends of patient response to different Pregabalin dosages compared to placebo.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing the relationship between percent improvement in pain from baseline (x-axis) and percent of patients improved (y-axis) for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph compares the effectiveness of the two doses of Pregabalin against placebo in patient pain improvement over a range of percentages.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The vertical axis shows percentage of patients improved, and the horizontal axis shows percentage improvement in pain.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) across different doses and placebo groups in two separate studies, Study E1 and Study E3. The x-axis shows treatment groups including placebo and varying dosages, while the y-axis shows responder rates from 0% to 60%. Study E1 includes placebo and doses from 50mg/day to 600mg/day twice daily (BID). Study E3 includes placebo, 300mg/day BID, and 600mg/day three times daily (TID). Responder rates increase with dosage in both studies, with statistically significant differences indicated versus placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting seizure reduction as median percentage change from baseline relative to daily dose (mg/day) of Pregabalin. The graph compares multiple studies (E1, E2, and E3) with dosing schedules of twice daily (BD) and thrice daily (TID), showing dose-dependent increases in seizure reduction. Significant p-values are indicated for various dose points.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 300 mg, 450 mg, and 800 mg daily doses compared to placebo. The graph includes four curves representing each treatment and placebo, illustrating their relative effectiveness in pain improvement.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the percentage of subjects without LTR over time (days) between Pregabalin and placebo groups. The vertical axis shows the estimated percentage of subjects without LTR from 0% to 100%, and the horizontal axis shows days from 0 to 180. The Pregabalin group has a higher percentage of subjects without LTR across the period compared to the placebo group.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved on Pregabalin versus placebo. The x-axis shows percent improved from baseline to week 12 BOCF, ranging from 0 to 100. The y-axis indicates the percent of subjects improved. The solid line represents Pregabalin with higher improvement percentages than the dotted placebo line over the range.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph depicting the percent of subjects improved on the vertical axis against the percent improved from baseline to week 16 on the horizontal axis. Two lines compare Pregabalin and placebo, with Pregabalin consistently showing a higher percentage of subjects improved across the percentage range.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A text panel displaying the formula for creatinine clearance (CLcr) calculation: CLcr equals 140 minus age in years, multiplied by weight in kilograms, divided by 72 times serum creatinine in mg/dL, with a multiplier of 0.85 for female patients.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin showing its molecular arrangement with labeled functional groups including an amino group (NH2) and a carboxylic acid group (CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.